From this study cohort, there were 2348 Luminal A/B (ER or PR-positive) cases, 41 HER-2 (ER and PR-negative and HER-2-positive) cases, and 85 triple-negative breast cancer TNBC (ER, PR, and HER-2- negative) cases. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.